Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MDX-CTLA-4: Phase II

Preliminary analysis of a U.S. Phase II study in 14 patients given

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE